Treatment-focused Ebola trials, supportive care and future of filovirus care

Maryam Keshtkar-Jahromi, Karen A.O. Martins, Anthony P. Cardile, Ronald B. Reisler, George W. Christopher, Sina Bavari

Research output: Contribution to journalReview article

Abstract

Introduction: During the 2014–2016 Ebolavirus (EBOV) outbreak, several candidate therapeutics were used in EBOV-infected patients in clinical trials and under expanded access for emergency use. This review will focus briefly on medications used during the outbreak. We will discuss current therapeutic candidates and their status and will then turn to a related and essential topic: supportive care and the standard of care for filovirus infected patients. Potential benefits and pitfalls of combination therapies for filoviruses will be discussed. Areas covered: Clinical trials of therapeutics targeting EBOV; clinical usage of therapeutics during recent EBOV outbreak; potential need for combination therapy; role of supportive care in treatment of Ebola virus disease (EVD). Expert commentary: In the absence of another large scale EBOV outbreak, the path to therapeutic product licensure in the United States of America (USA) would need to be via the FDA Animal Rule. However, human data may be needed to supplement animal data. The future of filovirus therapeutics may therefore benefit by establishing the ability to implement clinical trials in an outbreak setting in a timely fashion. Supportive care guidelines for filovirus infection should be defined and established as standard of care for treatment of EVD.

Original languageEnglish (US)
Pages (from-to)67-76
Number of pages10
JournalExpert Review of Anti-Infective Therapy
Volume16
Issue number1
DOIs
StatePublished - Jan 2 2018

Fingerprint

Ebolavirus
Disease Outbreaks
Ebola Hemorrhagic Fever
Standard of Care
Therapeutics
Clinical Trials
Licensure
Emergencies
Guidelines
Infection

Keywords

  • Clinical Trials
  • Ebola
  • Filovirus
  • supportive care
  • therapeutics

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Treatment-focused Ebola trials, supportive care and future of filovirus care. / Keshtkar-Jahromi, Maryam; Martins, Karen A.O.; Cardile, Anthony P.; Reisler, Ronald B.; Christopher, George W.; Bavari, Sina.

In: Expert Review of Anti-Infective Therapy, Vol. 16, No. 1, 02.01.2018, p. 67-76.

Research output: Contribution to journalReview article

Keshtkar-Jahromi, Maryam ; Martins, Karen A.O. ; Cardile, Anthony P. ; Reisler, Ronald B. ; Christopher, George W. ; Bavari, Sina. / Treatment-focused Ebola trials, supportive care and future of filovirus care. In: Expert Review of Anti-Infective Therapy. 2018 ; Vol. 16, No. 1. pp. 67-76.
@article{4a8743c88a254fb28ab4301637b1ffd6,
title = "Treatment-focused Ebola trials, supportive care and future of filovirus care",
abstract = "Introduction: During the 2014–2016 Ebolavirus (EBOV) outbreak, several candidate therapeutics were used in EBOV-infected patients in clinical trials and under expanded access for emergency use. This review will focus briefly on medications used during the outbreak. We will discuss current therapeutic candidates and their status and will then turn to a related and essential topic: supportive care and the standard of care for filovirus infected patients. Potential benefits and pitfalls of combination therapies for filoviruses will be discussed. Areas covered: Clinical trials of therapeutics targeting EBOV; clinical usage of therapeutics during recent EBOV outbreak; potential need for combination therapy; role of supportive care in treatment of Ebola virus disease (EVD). Expert commentary: In the absence of another large scale EBOV outbreak, the path to therapeutic product licensure in the United States of America (USA) would need to be via the FDA Animal Rule. However, human data may be needed to supplement animal data. The future of filovirus therapeutics may therefore benefit by establishing the ability to implement clinical trials in an outbreak setting in a timely fashion. Supportive care guidelines for filovirus infection should be defined and established as standard of care for treatment of EVD.",
keywords = "Clinical Trials, Ebola, Filovirus, supportive care, therapeutics",
author = "Maryam Keshtkar-Jahromi and Martins, {Karen A.O.} and Cardile, {Anthony P.} and Reisler, {Ronald B.} and Christopher, {George W.} and Sina Bavari",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/14787210.2018.1413937",
language = "English (US)",
volume = "16",
pages = "67--76",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Treatment-focused Ebola trials, supportive care and future of filovirus care

AU - Keshtkar-Jahromi, Maryam

AU - Martins, Karen A.O.

AU - Cardile, Anthony P.

AU - Reisler, Ronald B.

AU - Christopher, George W.

AU - Bavari, Sina

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Introduction: During the 2014–2016 Ebolavirus (EBOV) outbreak, several candidate therapeutics were used in EBOV-infected patients in clinical trials and under expanded access for emergency use. This review will focus briefly on medications used during the outbreak. We will discuss current therapeutic candidates and their status and will then turn to a related and essential topic: supportive care and the standard of care for filovirus infected patients. Potential benefits and pitfalls of combination therapies for filoviruses will be discussed. Areas covered: Clinical trials of therapeutics targeting EBOV; clinical usage of therapeutics during recent EBOV outbreak; potential need for combination therapy; role of supportive care in treatment of Ebola virus disease (EVD). Expert commentary: In the absence of another large scale EBOV outbreak, the path to therapeutic product licensure in the United States of America (USA) would need to be via the FDA Animal Rule. However, human data may be needed to supplement animal data. The future of filovirus therapeutics may therefore benefit by establishing the ability to implement clinical trials in an outbreak setting in a timely fashion. Supportive care guidelines for filovirus infection should be defined and established as standard of care for treatment of EVD.

AB - Introduction: During the 2014–2016 Ebolavirus (EBOV) outbreak, several candidate therapeutics were used in EBOV-infected patients in clinical trials and under expanded access for emergency use. This review will focus briefly on medications used during the outbreak. We will discuss current therapeutic candidates and their status and will then turn to a related and essential topic: supportive care and the standard of care for filovirus infected patients. Potential benefits and pitfalls of combination therapies for filoviruses will be discussed. Areas covered: Clinical trials of therapeutics targeting EBOV; clinical usage of therapeutics during recent EBOV outbreak; potential need for combination therapy; role of supportive care in treatment of Ebola virus disease (EVD). Expert commentary: In the absence of another large scale EBOV outbreak, the path to therapeutic product licensure in the United States of America (USA) would need to be via the FDA Animal Rule. However, human data may be needed to supplement animal data. The future of filovirus therapeutics may therefore benefit by establishing the ability to implement clinical trials in an outbreak setting in a timely fashion. Supportive care guidelines for filovirus infection should be defined and established as standard of care for treatment of EVD.

KW - Clinical Trials

KW - Ebola

KW - Filovirus

KW - supportive care

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85040087155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040087155&partnerID=8YFLogxK

U2 - 10.1080/14787210.2018.1413937

DO - 10.1080/14787210.2018.1413937

M3 - Review article

C2 - 29210303

AN - SCOPUS:85040087155

VL - 16

SP - 67

EP - 76

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 1

ER -